AIM: Glucocorticoid (GC) resistant ulcerative colitis (UC)remains a serious disease and is difficult to manage.Although the molecular basis of GC insensitivity
AIM: To assess the efficacy of ribavirin monotherapy in patients with biochemical relapse after combination therapy.METHODS: Twenty-four weeks of ribavirin mono